Apricity Therapeutics Overview
- Founded
-
2012

- Status
-
Private
- Employees
-
2

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$168K
- Investors
-
4
Apricity Therapeutics General Information
Description
Developer of exploit solute carrier transporter platform for pushing chemotherapy agents directly to tumors intended to treat pediatric cancers. The company is building a solute carrier transporter platform to improve drug pharmacological effects, reduce drug toxicity, and target transporters that can be inhibited to treat human diseases.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 953 Indiana Street
- San Francisco, CA 94107
- United States
Apricity Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
8. Grant | 01-Jan-2020 | $168K | Completed | Startup | ||
7. Grant | 01-Jan-2019 | 00000 | Completed | Startup | ||
6. Grant | 01-Jan-2017 | 00000 | Completed | Startup | ||
5. Grant | 01-Jan-2016 | 00000 | Completed | Startup | ||
4. Grant | 01-Jan-2014 | 00000 | Completed | Startup | ||
3. Grant | 01-Jan-2012 | 00000 | Completed | Startup | ||
2. Accelerator/Incubator | 19-Sep-2012 | Completed | Startup | |||
1. Accelerator/Incubator | Completed | Startup |
Apricity Therapeutics Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Kathleen Giacomini Ph.D | Co-Founder & Scientific Advisor |
Apricity Therapeutics Signals
Apricity Therapeutics Investors (4)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
QB3 | Accelerator/Incubator | 000 0000 | 000000 0 | ||
National Institutes of Health | Government | 000 0000 | 000000 0 | ||
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | 000 0000 | 000000 0 |